Black Americans have the highest rates of Alzheimer’s disease and related dementias in the United States. Older Black Americans are about twice as likely as older white Americans to develop the condition. Older Hispanic Americans follow, at roughly one and a half times the rate of white Americans. Asian Americans, by contrast, show a lower likelihood of developing Alzheimer’s compared to other racial groups.
These numbers reflect a complex mix of biology, systemic health inequities, cardiovascular risk, and diagnostic bias. Race itself doesn’t cause Alzheimer’s, but the conditions that cluster around race in America, from chronic disease rates to education access to neighborhood quality, clearly shape who gets it and when it’s caught.
Prevalence Across Racial Groups
The disparity is starkest between Black and white Americans. Across studies, Black Americans consistently face roughly double the risk. Hispanic Americans fall in between, at about 1.5 times the risk of white Americans. Among American Indian and Alaska Native populations, diagnoses are rising fast, with researchers projecting a fivefold increase in Alzheimer’s diagnoses by 2060. In that group, mortality rates climbed 22% between 2011 and 2019.
Asian Americans as a broad group appear to have lower rates, though this masks important variation. Korean Americans may face elevated risk due to higher levels of alcohol and tobacco use, and Pacific Islanders carry the Alzheimer’s-associated gene variant at rates four times higher than expected, a pattern researchers are still working to explain. Underdiagnosis also clouds the picture: only 18% of Asian Americans are aware of mild cognitive impairment, and more than half believe significant memory loss is a normal part of aging. These gaps in awareness almost certainly mean cases go uncounted.
Why Black Americans Are Hit Hardest
No single factor explains the disparity. Instead, several overlapping forces push the numbers higher.
Cardiovascular conditions play a major role. Stroke, diabetes, high blood pressure, and obesity all raise the risk of cognitive decline, and most of these conditions are more common in Black and Hispanic Americans. One study estimated that simply closing the racial gap in Type 2 diabetes incidence could reduce dementia cases by 17%. Vascular dementia, a type of cognitive decline driven by blood vessel damage, also accounts for a larger share of dementia cases in Black Americans than in white Americans.
That said, cardiovascular disease doesn’t fully account for the gap. In at least two major studies, the higher Alzheimer’s rate among Black Americans persisted even after researchers controlled for heart disease, stroke, and diabetes. Something beyond vascular health is involved.
The Role of Genetics
The gene most strongly linked to Alzheimer’s risk is called APOE-e4. Carrying one or two copies of it raises your likelihood of developing the disease. But the risk isn’t equal across populations. Research published in PLOS Genetics found that people who inherited the region of DNA surrounding this gene from African ancestors faced lower Alzheimer’s risk than those who inherited the same gene variant from European ancestors. Protective genetic variants on the African ancestral background appear to blunt the effect.
This creates a paradox: Black Americans carry the high-risk gene variant at notable rates, yet the gene itself appears to be less dangerous in people with African genetic ancestry. The reasons are still unclear, but researchers have ruled out broad cultural or lifestyle differences as the explanation. Population-specific genetic factors near the APOE gene are the leading candidate.
Later Diagnosis, Worse Outcomes
Black Americans aren’t just more likely to develop Alzheimer’s. They’re also more likely to be diagnosed later in the disease, when symptoms are already severe. Data from the National Institute on Aging’s network of Alzheimer’s research centers showed that Black participants had greater cognitive impairment and more severe symptoms at the time of diagnosis compared to white participants.
The pattern suggests a systemic problem with how the disease gets recognized. Black patients were about twice as likely as white patients to experience delusions and hallucinations by the time they received a diagnosis, even after adjusting for education and demographic factors. Researchers interpret this as evidence that Black patients often need to present with more advanced symptoms before physicians make the diagnosis. Multiple studies have confirmed that Black individuals tend not to receive an Alzheimer’s diagnosis or seek treatment until the disease has progressed significantly.
Diagnostic Tools May Work Differently
Some of the newer blood-based tests for Alzheimer’s don’t perform equally across racial groups. Researchers at Washington University found that a blood test measuring one specific protein fragment (a ratio of amyloid proteins) predicted brain amyloid buildup consistently in both Black and white participants. But other blood markers, including two forms of a protein called phosphorylated tau and a nerve damage marker, performed inconsistently. In Black participants, these markers significantly underestimated the likelihood of brain amyloid buildup compared to white participants.
The practical consequence: if screening relies on the wrong blood marker, Black patients could be disproportionately told they don’t have Alzheimer’s when they actually do. This adds another layer to the diagnostic gap already created by clinical bias.
Social and Environmental Factors
Education level is one of the strongest non-genetic predictors of brain health. Adults over 45 without a high school diploma experience worsening memory and confusion at more than twice the rate of college graduates. The concept behind this is cognitive reserve: years of education and intellectual engagement build a buffer that helps the brain compensate as it ages. Generations of unequal access to quality education have left Black and Hispanic Americans with less of that buffer on average.
Neighborhood environment matters too. The physical spaces where people live shape opportunities for exercise, healthy eating, and social connection, all of which protect brain health. Unsafe or poorly designed neighborhoods with limited walkability and few services work against cognitive health over a lifetime. Among American Indian and Alaska Native communities, researchers found that people in more economically deprived counties had a 34% higher risk of Alzheimer’s mortality. But there was also a surprising protective finding: for every 10% increase in the local AI/AN population, Alzheimer’s mortality risk dropped 14%, suggesting that community cohesion and cultural connection may serve as a buffer.
Underrepresentation in Research
The populations most affected by Alzheimer’s are the least represented in the studies designed to understand and treat it. In Alzheimer’s neuroimaging research, 87% of participants in direct studies were non-Hispanic white. Black participants made up just 7.3%, Hispanic participants 3.4%, and Asian American, Native Hawaiian, Pacific Islander, and American Indian participants were essentially absent at 0%. Representation of Black participants has improved, rising from about 3.4% before 2017 to 8.3% in more recent years, but the gap remains enormous relative to the disease burden these communities carry.
This underrepresentation has real consequences. Treatments developed and tested primarily in white populations may not work identically in other groups. Diagnostic thresholds calibrated on white patients may miss the disease in others. And the distrust this creates is self-reinforcing: nearly half of Asian Americans believe medical research is biased against people of color, which discourages participation in the studies that could close these gaps.